To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% in the Treatment of Scalp Psoriasis

  • STATUS
    Not Recruiting
  • participants needed
    604
  • sponsor
    Glenmark Pharmaceuticals Ltd. India
Updated on 22 January 2021

Summary

This is a phase III, randomized, double-blind, placebo-controlled, parallel- group, multiple-site study to evaluate the therapeutic equivalence of generic calcipotriene and betamethasone dipropionate topical suspension, 0.005%/0.064% of Glenmark Pharmaceuticals Ltd to that of the marketed product Taclonex topical suspension of Leo Pharma Inc. in the treatment of scalp psoriasis.

Details
Condition Scalp Psoriasis
Treatment Placebo, Calcipotriene/Betamethasone Dipropionate, Taclonex®
Clinical Study IdentifierNCT03331523
SponsorGlenmark Pharmaceuticals Ltd. India
Last Modified on22 January 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note